Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? Hamadani M. Haematologica 2022;107:1500-1502.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hamadani M. Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? Haematologica 2022;107:1500-1502.
PMID: 34965703